Tuesday 22 October 2019 ,
Tuesday 22 October 2019 ,
Latest News
  • It's a responsibility for all to ensure road safety: PM
  • One-minute digital account service kicks off
  • Bhola SP’s Facebook ID hacked
  • Govts, Internet companies fail to meet challenges of online hate: UN expert
  • National Road Safety Day today
8 July, 2019 00:00 00 AM

FDA approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin

drugs.com
FDA approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin

Amgen and Allergan plc recently announced that the U.S. Food and Drug Administration (FDA) has approved Kanjinti (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

"The FDA approval of Kanjinti is an important milestone for our biosimilars portfolio, providing an additional treatment option for patients across three types of cancer," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "Kanjinti is the third biosimilar from our portfolio to receive FDA approval, highlighting our long-term commitment to providing patients with serious illnesses access to high-quality biological therapies."

Kanjinti was proven to be highly similar to, and to have no clinically meaningful differences from, Herceptin based on a comprehensive totality of evidence which included extensive comparative analytical, pharmacokinetic and clinical data.

At the time of approval, Kanjinti is the only trastuzumab biosimilar to incorporate the evaluation of a single transition in the clinical study, demonstrating similar safety and immunogenicity in patients who were previously on Herceptin.

"Kanjinti is the second of four biosimilars from Amgen and Allergan's collaboration to be approved by the FDA," said David Nicholson, chief research and development officer at Allergan. "We are proud of the progress being made as we continuously strive to develop and deliver high-quality cancer therapies in collaboration with Amgen."

Kanjinti is approved for:

Adjuvant breast cancer

Kanjinti is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*) breast cancer:

As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel

With docetaxel and carboplatin

As a single agent following multi-modality anthracycline-based therapy

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.

Metastatic breast cancer

Kanjinti is indicated:

In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer

As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

Metastatic gastric cancer

Kanjinti is indicated:

in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease.

Warnings and important safety information Cardiomyopathy

Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens

Evaluate left ventricular function in all patients prior to and during treatment with Kanjinti™. Discontinue Kanjinti™ treatment in patients receiving adjuvant therapy and withhold Kanjinti™ in patients with metastatic disease for clinically significant decrease in left ventricular function

Infusion reactions; pulmonary toxicity

Administration of trastuzumab products can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration. Interrupt Kanjinti™ infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue Kanjinti™ for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

Embryo-fetal toxicity

Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception

Cardiomyopathy

Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. In a pivotal adjuvant breast cancer trial, one patient who developed CHF died of cardiomyopathy

Trastuzumab can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death

Trastuzumab can also cause asymptomatic decline in LVEF

Discontinue Kanjinti™ treatment in patients receiving adjuvant breast cancer therapy and withhold Kanjinti™ in patients with metastatic disease for clinically significant decrease in left ventricular function

Cardiac monitoring

Evaluate cardiac function prior to and during treatment. For adjuvant breast cancer therapy, also evaluate cardiac function after completion of Kanjinti™

Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan

Monitor frequently for decreased left ventricular function during and after Kanjinti™ treatment

Monitor more frequently if Kanjinti™ is withheld for significant left ventricular cardiac dysfunction

Infusion reactions

Kanjinti™ administration can result in serious and fatal infusion reactions

Symptoms usually occur during or within 24 hours of Kanjinti™ administration

Interrupt Kanjinti™ infusion for dyspnea or clinically significant hypotension

Monitor patients until symptoms completely resolve

Discontinue Kanjinti™ for infusion reactions manifesting as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Strongly consider permanent discontinuation in all patients with severe infusion reactions

Infusion reactions consist of a symptom complex characterized by fever and chills, and on occasion include nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, dyspnea, hypotension, rash, and asthenia

Embryo-fetal toxicity

Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception

Verify the pregnancy status of females of reproductive potential prior to the initiation of Kanjinti™

Advise pregnant women and females of reproductive potential that exposure to Kanjinti™ during pregnancy or within 7 months prior to conception can result in fetal harm

Advise females of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose of Kanjinti™. Advise female patients to contact their healthcare provider with a known or suspected pregnancy

Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for Kanjinti™ treatment and any potential adverse effects on the breastfed child from Kanjinti™ or from the underlying maternal condition

Pulmonary toxicity

Trastuzumab products can result in serious and fatal pulmonary toxicity, which includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, noncardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Such events can occur as sequelae of infusion reactions. Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicity. Discontinue Kanjinti inpatients experiencing pulmonary toxicity

Exacerbation of chemotherapy-induced Neutropenia

In randomized, controlled clinical trials, the per-patient incidences of NCI-CTC Grade 3-4 neutropenia and of febrile neutropenia were higher in patients receiving trastuzumab in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic death was similar among patients who received trastuzumab and those who did not. 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Osteoporosis is commonest metabolic bone disease, occurs in old age and different from osteomalacia - rickets. There is progressive decrease in the density…
Osteoporosis

Osteoporosis

Osteoporosis is a condition characterized by a decrease in the density of bone, decreasing its strength and resulting in fragile bones. Osteoporosis literally…
WHO criteria for diagnosis of osteoporosis

WHO criteria for diagnosis of osteoporosis

Under the auspices of the World Health Organization (WHO), a panel of experts has periodically met on the topic of assessment of fracture risk and osteoporosis.…
Osteoporosis: An epidemic with dire consequences

Osteoporosis: An epidemic with dire consequences

Osteoporosis, which literally means porous bone, is reduced bone mass per unit volume thus predisposing the person with it to an increased risk of fracture.…
An overview of juvenile osteoporosis

An overview of juvenile osteoporosis

LANA BARHUM Osteoporosis a progressive bone disease where bone density is lost or there is insufficient bone formation. The result is weakened bones and…
How to cope with some of the most difficult menopause symptoms

How to cope with some of the most difficult menopause symptoms

 ALICE OGLETHORPE Menopause happens to every single woman, but that doesn’t mean the symptoms—or best treatments—are the same for…
Melanoma stages: Prognosis, survival rates and treatment

Melanoma stages: Prognosis, survival rates and treatment

LISA ESPOSITO Melanoma is one of the most serious forms of skin cancer. In early stages, it may be treated through relatively simple surgery, but advanced…
When to be concerned about constant ringing in your ears

When to be concerned about constant ringing in your ears

 BETH KRIETSCH Have you ever experienced ringing, buzzing, hissing or other noises that no one else around you seems to hear — and you wonder…
The health benefits of cinnamon essential oil

The health benefits of cinnamon essential oil

CATHY WONG Cinnamon essential oil is a type of essential oil used in aromatherapy. The oil has a warm, sweet aroma, and is sourced from the bark of the…
5th International Medical Mission 2019 held in Dhaka

5th International Medical Mission 2019 held in Dhaka

Week-long 5th International Medical Mission held in Dhaka from 12-17 October 2019 organized by Rotary Club of Dhaka Mavericks with the collaboration of…
Microphone could diagnose 'noisy' arthritic knees

Microphone could diagnose 'noisy' arthritic knees

Technology used by engineers to listen for faults in bridges could be used to diagnose 'noisy' arthritic knees, a study suggests. It involved…
1st Scientific Congress on Non-communicable Diseases held in Dhaka

1st Scientific Congress on Non-communicable Diseases held in Dhaka

The Clinical Research Platform, Bangladesh, a tripartite initiative of icddr,b, Bangabandhu Sheikh Mujib Medical University (BSMMU) and the British Medical…
Lilly's REYVOW™ (lasmiditan), the first and only medicine in a new class of acute treatment for migraine, receives FDA approval

Lilly's REYVOW™ (lasmiditan), the first and only medicine in a new class of acute treatment for migraine, receives FDA approval

Eli Lilly and Company (LLY) announced recently that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting